Elmar Zurbriggen appointed as CEO of AOT, Peter Oprandi as CFO

Advanced Osteotomy Tools (AOT) has appointed Elmar Zurbriggen as its new CEO. Simultaneously, Peter Oprandi will become CFO of the Basel-based MedTech company. They will start in their new roles as of April 1, 2022.

“Elmar and Peter have both gained decades of experience as senior managers in the life science sector, working for global market leaders such as Johnson & Johnson, Depuy Synthes, AstraZeneca and Lonza,” says Dr. Erich Platzer, Chairman of AOT’s Board of Directors. “We are delighted that they are now supporting AOT as CEO and CFO. Our goal is to improve patient care with innovative high-tech products. Elmar and Peter are exactly the right leaders for this.”

The Swiss MedTech company AOT is best known for developing the surgical robot CARLO, which is the world’s first certified surgical device to cut bone with a laser.

Elmar Zurbriggen is an internationally accomplished senior management professional with broad leadership experience in the life science industry (20 years medtech, 10 years biotech). He has excellent track records in areas such as international sales and marketing, strategy development and implementation, M&A integration and change management, product development, innovation and finance.

I’m excited to work with a brilliant team of engineers and clinical specialists to further improve CARLO and make it available to patients around the world. CARLO is expected to receive FDA approval for the U.S. market as well as certification for other areas of application – such as orthopaedic surgery – within this year. Laser is the future of bone surgery. Being able to help shape this future is extremely motivating.

Elmar Zurbriggen, CEO of AOT

Peter Oprandi has extensive international experience as a strategic finance and business leader with CDMOs, multinationals, start-ups and private equity. His activities in Europe, North and South America as well as Asia cover areas such as finance, audit, controlling, BD&L, supply chain, OE and operations. As part of his broad involvement in life sciences, he has been building effective partnerships between companies and investors for years.

CARLO is a true game changer that demonstrates how AOT’s patented technologies are advancing surgery. I am happy to be part of this success story and full of anticipation for the road ahead.

Peter Oprandi, CFO of AOT